Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Thomas Civik
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 56
- Beta
- 1.38
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -15.86
Financials
Revenue
$0.00-100.0%Net Income
$-25.35MEBITDA
$-25.05MFree Cash Flow
$-18.21MEPS (diluted)
$-0.40Shares Outstanding (diluted)
63.99M+6826.1%Operating Expenses
$25.99MCash & Debt
$33.00MReturn of Capital
$0.00Revenue by Segment (annual)
$2.82MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $13.86M | $-79.62M | $-1.28 |
| 2024 | $16.15M | $-77.33M | $-1.32 |
| 2023 | $0.00 | $-73.79M | $-1.85 |
| 2022 | $0.00 | $-120.72M | $-3.57 |
| 2021 | $0.00 | $-75.97M | $-2.53 |
| 2020 | $0.00 | $-12.83M | $-0.37 |
| 2019 | $0.00 | $-2.77M | $-0.08 |
Valuation
PYXShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
53+6.67%Social Signal Score
Mentions (9)
- Newsseekingalpha.com·20d ago·Neutral
Pyxis Oncology: Better Runway Is Bullish For MICVO's Remaining R&D PYXS's main value driver is MICVO. This is an oncology drug candidate that could be useful for killing cancerous cells. MICVO's early data has been promising, but PYXS still has to find an adequate dose that's safe and effective. Fortunately, PYXS's recent raise helps their financing in the near term and should be enough for them to reach important clinical milestones with MICVO.
View source ↗ - Newsglobenewswire.com·22d ago·Negative
Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS or the “Company”), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it closed its previously announced registered public offering (the "Offering") on October 1, 2026. The Offering generated approximately $110.0 million in upfront gross proceeds, before deducting underwriting disco…
View source ↗ - Newsglobenewswire.com·24d ago·Negative
Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the pricing of its previously announced registered public offering (the "Offering") of 36,047,919 shares of its common stock, or in lieu of common stock to certain investors, 1,883,121 pre-funded warrants to purchase shares of common …
View source ↗ - Newsglobenewswire.com·25d ago·Negative
Pyxis Oncology Announces Proposed Public Offering BOSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it has commenced a registered public offering (the "Offering") of (i) shares of its common stock, or in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock, and (ii) accompanying common warrants to purchase…
View source ↗ - Newsseekingalpha.com·44d ago·Positive
Pyxis Oncology, Inc. (PYXS) Discusses MICVO Monotherapy Phase I Clinical Data in Head and Neck Squamous Cell Carcinoma Transcript Pyxis Oncology, Inc. (PYXS) Discusses MICVO Monotherapy Phase I Clinical Data in Head and Neck Squamous Cell Carcinoma Transcript
View source ↗ - Newsbenzinga.com·45d ago·Negative
Pyxis Oncology Analyst Flags Key Safety Liabilities from Cancer Drug Pyxis Oncology Inc. (NASDAQ:PYXS) on Wednesday shared updated data from its Phase 1 trial evaluating micvotabart pelidotin (MICVO).
View source ↗ - Newsglobenewswire.com·46d ago·Neutral
Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it will host a live webcast on September 9, 2026 at 7:30 a.m.
View source ↗ - Newsglobenewswire.com·46d ago·Neutral
…rship transition reflects continued focus on advancing MICVO through key clinical milestones BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, announced today that its Board of Directors has appointed Thomas Civik as Chief Executive Officer and Chairman of the Board, effective as of September 4, 2026.
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
Pyxis Oncology to Participate in Upcoming Investor Conferences BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Tom Civik, Interim Chief Executive Officer and Director of Pyxis Oncology, will participate in fireside chats at three upcoming conferences.
View source ↗
Earnings
Mon, Nov 2(in 8 days)
Consensus estimate $-0.27 per share
Typical surprise -5.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.40 vs $-0.35miss
- Thu, May 14$-0.37 vs $-0.35miss
- Mon, Mar 23$-0.29 vs $-0.35beat
- Mon, Nov 3$-0.35 vs $-0.36beat
- Thu, Aug 14$-0.30 vs $-0.36beat
- Thu, May 15$-0.35 vs $-0.29miss
Estimates and results for PYXS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PYXS officers and directors.
- Bought
- $51.8m
- Sold
- $204k
12 trades
9 trades
- Gordonmd Global Investments Lpbought
- Gordonmd Global Investments Lpbought
- Gordonmd Global Investments Lpbought
- Dupont Jakobsold
- Humphrey Rachelsold
- Humphrey Rachelsold
- Humphrey Rachelsold
- Connealy Pamela Annbought
79 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PYXS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.